Lee Gary K.
Known title: Chief Scientific OfficerCIK: 0001907345
Associated companies
Transaction History
| LYEL | ▼ Sell | Open Market | 1,457 | $23K | 8/21/2026 | View on chart |
| LYEL | ▼ Sell | Open Market | 131 | $2K | 8/10/2026 | View on chart |
| LYEL | ▼ Sell | Open Market | 130 | $2K | 5/11/2026 | View on chart |
| LYEL | ▼ Sell | Open Market | 1,671 | $39K | 2/11/2026 | View on chart |
| LYEL | ▼ Sell | Open Market | 147 | $3K | 2/10/2026 | View on chart |
| LYEL | ▲ Buy | Grant | 4,000 | $0 | 2/9/2026 | View on chart |
| LYEL | ▼ Sell | Open Market | 138 | $2K | 11/10/2025 | View on chart |
| LYEL | ▼ Sell | Open Market | 1,453 | $15K | 8/21/2025 | View on chart |
| LYEL | ▲ Buy | Grant | 8,000 | $0 | 8/20/2025 | View on chart |
| LYEL | ▼ Sell | Open Market | 136 | $1K | 8/12/2025 | View on chart |
| LYEL | ▼ Sell | Open Market | 131 | $1K | 8/11/2025 | View on chart |
| LYEL | ▲ Buy | Grant | 112,500 | $0 | 2/10/2025 | View on chart |
| LYEL | ▲ Buy | Grant | 40,000 | $0 | 2/9/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Lyell Immunopharma shares fall 27% over four weeks
The stock has dropped about 27% in the past month, prompting a Yahoo article that discusses factors that could support a recovery. The piece notes the recent price weakness and points to potential catalysts that may improve sentiment. The decline leaves the share price near a key support level and the RSI is low, indicating oversold conditions.
Lyell Immunopharma shares fall 27% over four weeks. The stock has dropped about 27% in the past month, prompting a Yahoo article that discusses factors that could support a recovery. The piece notes the recent price weakness and points to potential catalysts that may improve sentiment. The decline leaves the share price near a key support level and the RSI is low, indicating oversold conditions.